Assessment of “T2D Remission” Status of a Long-Term Type 2 Diabetes Patient Using the 2021 Consensus Report Sponsored by American Diabetes Association Based on GH-Method: Math-Physical Medicine (No. 505)

DOI: https://doi.org/10.33140/abbsr.04.003

2021-12-15

Advances in Bioengineering and Biomedical Science Research

Abstract:The author has suffered from type 2 diabetes (T2D) for over 26 years and had complications related to his heart, kidney, eyes, foot, bladder, thyroid, etc. In 1995, he started taking Metformin, which led to two additional types of diabetes medications in high dosages. It took him three years to gradually decreased the dosages for each medication from 2013 to 2015, and ceased all of them on 12/8/2015. He started to implement a lifestyle management program step-by-step in mid-2015 at a slow and steady pace. His lifestyle program not only focuses on diet and exercise but also factors in sleep, stress, life habits, and environmental factors. This introduction is a brief overview of his long history of diabetes fighting. A detailed personal history of the author can be found in the methods section. On 9/1/2021, he read a consensus report regarding the definition and interpretation of remission in T2D published on 8/30/2021. He wondered where was his standing according to the new guidelines described in this consensus report? Therefore, he must reorganize his collected personal big data (>2 million) according to the definition of “remission” which includes timespan requirements, HbA1C severity, fasting plasma glucose (FPG) level, estimated HbA1C (eA1C) values based on both mean finger glucoses and mean continuous glucose monitoring (CGM) glucoses. In addition, he sorted his collected mean carbohydrates & sugar intake amount per meal (positive stimulator for energy infusion) and mean post-meal walking steps per meal (negative stimulator for energy consumption) which are closely related to his glucoses. In conclusion, according to the American Diabetes Association (ADA) 2021 consensus report, the author is in a “remission” state of T2D. In summary, over the selected one-year period from 9/1/2020 to 9/1/2021, his average Lab-A1C is 6.3%, FPG values are 94 mg/dL (finger FPG) and 101 mg/dL (CGM FPG), and CGM eAG is 6.0%. First, his selected timespan of past one year satisfies the timespan requirement from 2021 consensus report. This set of his glucose data is almost 5 years post-cessation of his medication intervention and initiation of his stringent lifestyle management program.